PATISIRAN

Brand name:

• Onpattro®

Pharmaceutical company:

ALNYLAM AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)

PBAC Submission type:

New PBS listing (Early Resolution Pathway)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – September 2023 meeting

Related medicines:

• PATISIRAN

Submission received for:

September 2023 PBAC meeting

Opportunity for consumer comment:

Open 29/03/2023 and close 24/05/2023 (see PBS Website)

PBAC meeting:

Held on 01/09/2023

PBAC outcome published:

Deferred (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---